8 results
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
To examnine the effectiveness of psychological interventions and psychopharmacological interventions compared to placebo-control.
The objective of this study is to assess the effects of an increased NE level on the trade-off between exploitation and exploration. More specifically, this study will compare the exploitative/explorative behavior of participants who received either…
The primary objective is to examine whether a combined treatment with rivastigmine (cholinesterase inhibitor) and citalopram (selective serotonin re-uptake inhibitor) will improve memory as compared to the treatment with either rivastigmine or…
We propose to conduct a study in healthy young and elderly subjects and patients diagnosed with mild to moderate AD, FTLD, or DLB where cholinergic and serotonergic challenges are given in a placebo-controlled, crossover fashion. Before each…
To assess the effect of citalopram on symptoms of chest pain in patients with functional chest pain.
To examine in depressed patients who reach a stable depression remission during optimal AD treatment: 1) whether discontinuation is possible; 2) when discontinuation is possible; and 3) in whom discontinuation is possible.
To assess the effect of citalopram on chest pain in patients with achalasia and to evaluate the effect of citalopram on esophageal sensitivity.